Tobramycin
Identification
- Name
- Tobramycin
- Accession Number
- DB00684
- Description
An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the pseudomonas species. It is a 10% component of the antibiotic complex, nebramycin, produced by the same species.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Tobramycin (DB00684)
- Weight
- Average: 467.5145
Monoisotopic: 467.259127807 - Chemical Formula
- C18H37N5O9
- Synonyms
- 3'-Deoxykanamycin B
- Nebramycin 6
- O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
- Tobramicina
- Tobramycin
- Tobramycine
- Tobramycinum
- External IDs
- 47663
- Lilly 47663
- SPRC-AB01
Pharmacology
- Indication
For the treatment of pseudomonas aeruginosa lung infections. Also being investigated for use in the treatment of sinus infections.
- Associated Conditions
- Bacterial Peritonitis
- Cystic fibrosis, Pseudomonas aeruginosa infection
- Eye Infections
- Inflammation of the External Auditory Canal
- Intra-Abdominal Infections
- Lower respiratory tract infection bacterial
- Meningitis, Bacterial
- Ocular Inflammation
- Septicemia gram-negative
- Skin and Subcutaneous Tissue Bacterial Infections
- Corticosteroid-responsive Disorder of the Ophthalmic
- Ear infection-not otherwise specified caused by susceptible bacteria
- Ocular bacterial infections
- Recurrent Complicated Urinary Tract Infection
- Steroid-responsive inflammation
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa.
- Mechanism of action
Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin.
Target Actions Organism A30S ribosomal protein S12 inhibitorEscherichia coli (strain K12) U16S ribosomal RNA inhibitorEnteric bacteria and other eubacteria - Absorption
The bioavailability of tobramycin may vary because of individual differences in nebulizer performance and airway pathology.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
The elimination half-life of tobramycin from serum is approximately 2 hours after intravenous (IV) administration.
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
LD50=441mg/kg (s.c. in mice)
- Affected organisms
- Enteric bacteria and other eubacteria
- Pathways
Pathway Category Tobramycin Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbacavir Tobramycin may decrease the excretion rate of Abacavir which could result in a higher serum level. Acarbose Tobramycin may decrease the excretion rate of Acarbose which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Tobramycin which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Tobramycin which could result in a higher serum level. Acenocoumarol The risk or severity of bleeding can be increased when Tobramycin is combined with Acenocoumarol. Acetaminophen Tobramycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. Acetylcholine The therapeutic efficacy of Acetylcholine can be decreased when used in combination with Tobramycin. Acetyldigitoxin The risk or severity of adverse effects can be increased when Tobramycin is combined with Acetyldigitoxin. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level. Aclidinium Tobramycin may decrease the excretion rate of Aclidinium which could result in a higher serum level. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- No interactions found.
Products
- Product Ingredients
Ingredient UNII CAS InChI Key Tobramycin hydrochloride 01IX3OU168 95188-93-5 CVDADWBWFLWJNQ-TWDWGCDDSA-N Tobramycin sulfate HJT0RXD7JK 49842-07-1 ZEUUPKVZFKBXPW-TWDWGCDDSA-N - International/Other Brands
- Aktob (Akorn) / Alveoterol (Tetrafarm) / Amgy (Kobec) / Bactob (Solitaire) / Belbarmicina (Quimica Luar) / Bideon Biotic (Fecofar) / Bioptic (Bausch & Lomb) / Bramitob (Torrex) / Gernebcin (Infectopharm) / Nebcin (Lilly) / Obracin (EuroCept) / Tobracin (Opso Saline) / Tobramaxin (Alcon)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataBethkis Solution 300 mg/4mL Respiratory (inhalation) Chiesi USA, Inc. 2013-04-15 Not applicable US 
Kitabis Pak Solution 300 mg/5mL Respiratory (inhalation) Pari Respiratory Equipment, Inc. 2015-02-19 Not applicable US Kitabis Pak Solution 300 mg/5mL Respiratory (inhalation) Catalent Pharma Solutions,Llc 2015-02-19 2018-03-22 US Nebcin Inj 1.2gm/30ml Liquid Intramuscular; Intravenous Eli Lilly & Co. Ltd. 1986-12-31 2003-05-12 Canada 
Nebcin Inj 10mg/ml Liquid Intramuscular; Intravenous Eli Lilly & Co. Ltd. 1975-12-31 2003-05-12 Canada Nebcin Inj 10mg/ml (vantage Vial) Liquid Intravenous Eli Lilly & Co. Ltd. 1989-12-31 1997-05-20 Canada Nebcin Inj 40mg/ml Liquid Intramuscular; Intravenous Eli Lilly & Co. Ltd. 1975-12-31 2003-05-12 Canada Nebcin Inj 60mg Liquid Intramuscular; Intravenous Eli Lilly & Co. Ltd. 1978-12-31 1998-08-04 Canada Nebcin Inj 80mg Liquid Intramuscular; Intravenous Eli Lilly & Co. Ltd. 1978-12-31 1998-08-04 Canada Tobi Solution 300 mg/5mL Oral Novartis Pharmaceuticals Corporation 1997-12-22 Not applicable US Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataAj-tobramycin Liquid Intramuscular; Intravenous Agila Jamp Canada Inc Not applicable Not applicable Canada Apo-tobramycin Solution Ophthalmic Apotex Corporation 2002-09-18 Not applicable Canada Jamp-tobramycin Solution Intramuscular; Intravenous Jamp Pharma Corporation 2014-03-11 Not applicable Canada PMS-tobramycin 0.3% Ophthalmic Solution Liquid Ophthalmic Pharmascience Inc 1999-02-18 2017-09-30 Canada Sandoz Tobramycin Solution Ophthalmic Sandoz Canada Incorporated 2000-08-21 Not applicable Canada Teva-tobramycin Solution Respiratory (inhalation) TEVA Canada Limited 2016-02-03 Not applicable Canada Tobramycin Solution / drops 3.0 mg/1mL Ophthalmic A-S Medication Solutions 2017-07-05 Not applicable US Tobramycin Solution 3 mg/1mL Ophthalmic Remedy Repack 2016-07-19 2017-03-06 US Tobramycin Solution / drops 3.0 mg/1mL Ophthalmic Rpk Pharmaceuticals, Inc. 2017-06-28 Not applicable US Tobramycin Solution / drops 3 mg/1mL Ophthalmic Stat Rx USA 1996-01-31 Not applicable US Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image TobraDex Tobramycin (3 mg/1g) + Dexamethasone (1 mg/1g) Ointment Ophthalmic Rebel Distributors 1988-09-28 Not applicable US TobraDex Tobramycin (3 mg/1mL) + Dexamethasone (1 mg/1mL) Suspension Ophthalmic A S Medication Solutions 1988-09-15 Not applicable US TobraDex Tobramycin (3 mg/1mL) + Dexamethasone (1 mg/1mL) Suspension / drops Ophthalmic ALCON LABORATORIES, INC. 1988-09-15 Not applicable US TobraDex Tobramycin (0.3 %) + Dexamethasone (0.1 %) Suspension Ophthalmic Novartis 1990-12-31 Not applicable Canada TobraDex Tobramycin (3 mg/1mL) + Dexamethasone (1 mg/1mL) Suspension Ophthalmic Rebel Distributors 1988-08-18 Not applicable US TobraDex Tobramycin (3 mg/1g) + Dexamethasone (1 mg/1g) Ointment Ophthalmic Novartis Pharmaceuticals Corporation 1988-10-15 Not applicable US TobraDex Tobramycin (3 mg/1g) + Dexamethasone (1 mg/1g) Ointment Ophthalmic Physicians Total Care, Inc. 1988-10-15 2010-06-30 US TobraDex Tobramycin (3 mg/1mL) + Dexamethasone (1 mg/1mL) Suspension Ophthalmic A S Medication Solutions 1988-09-15 Not applicable US TobraDex Tobramycin (3 mg/1g) + Dexamethasone (1 mg/1g) Ointment Ophthalmic ALCON LABORATORIES, INC. 1988-10-15 Not applicable US TobraDex Tobramycin (0.3 %) + Dexamethasone (0.1 %) Ointment Ophthalmic Novartis 1990-12-31 Not applicable Canada
Categories
- ATC Codes
- S01AA12 — TobramycinJ01GB01 — Tobramycin
- Drug Categories
- Agents that produce neuromuscular block (indirect)
- Aminoglycoside Antibacterials
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Carbohydrates
- Drugs that are Mainly Renally Excreted
- Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
- Glycosides
- Narrow Therapeutic Index Drugs
- Nebramycin
- Nephrotoxic agents
- Ophthalmologicals
- Sensory Organs
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 4,6-disubstituted 2-deoxystreptamines. These are 2-deoxystreptamine aminoglycosides that a glycosidically linked to a pyranose of furanose unit at the C4- and C6-positions.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- 4,6-disubstituted 2-deoxystreptamines
- Alternative Parents
- O-glycosyl compounds / Aminocyclitols and derivatives / Cyclohexylamines / Cyclohexanols / Oxanes / Monosaccharides / 1,2-aminoalcohols / Oxacyclic compounds / Acetals / Primary alcohols show 3 more
- Substituents
- 1,2-aminoalcohol / 4,6-disubstituted 2-deoxystreptamine / Acetal / Alcohol / Aliphatic heteromonocyclic compound / Amine / Aminocyclitol or derivatives / Cyclic alcohol / Cyclitol or derivatives / Cyclohexanol show 15 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- amino cyclitol glycoside (CHEBI:28864)
Chemical Identifiers
- UNII
- VZ8RRZ51VK
- CAS number
- 32986-56-4
- InChI Key
- NLVFBUXFDBBNBW-PBSUHMDJSA-N
- InChI
- InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
- IUPAC Name
- (2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol
- SMILES
- NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
References
- Synthesis Reference
Istvan Bakondi-Kovacs, "Metabolic controlled fermentation process for carbamoyl tobramycin production." U.S. Patent US20020197683, issued December 26, 2002.
US20020197683- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014822
- KEGG Drug
- D00063
- KEGG Compound
- C00397
- PubChem Compound
- 36294
- PubChem Substance
- 46507662
- ChemSpider
- 33377
- BindingDB
- 50366778
- 10627
- ChEBI
- 28864
- ChEMBL
- CHEMBL1747
- ZINC
- ZINC000008214692
- Therapeutic Targets Database
- DAP000110
- PharmGKB
- PA451704
- PDBe Ligand
- TOY
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Tobramycin
- AHFS Codes
- 08:12.02 — Aminoglycosides
- 52:04.04 — Antibacterials
- PDB Entries
- 1lc4 / 1m4d / 3sg8 / 3vet / 4ebk / 4evy / 4jd6 / 4lfc / 4xje / 5cfs … show 1 more
- FDA label
- Download (414 KB)
- MSDS
- Download (73.3 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Cystic Fibrosis (CF) 1 4 Completed Treatment Antibotics in Cementless Knees 1 4 Completed Treatment Blepharokeratoconjunctivitis 1 4 Completed Treatment Cataracts / Pseudoexfoliation Syndrome 1 4 Completed Treatment Chalazion / Hordeolum 1 4 Completed Treatment Conjunctivitis 1 4 Completed Treatment Cystic Fibrosis (CF) 4 4 Completed Treatment Fever / Malignancies / Neutropenia 1 4 Completed Treatment Inflammatory Reaction 1 4 Completed Treatment Knee Replacement Surgery 1
Pharmacoeconomics
- Manufacturers
- Alcon laboratories inc
- Akorn inc
- Alcon universal ltd
- Altana inc
- Bausch and lomb pharmaceuticals inc
- Novex pharma
- Falcon pharmaceuticals ltd
- Novartis pharmaceuticals corp
- Eli lilly and co
- Akorn strides llc
- Apothecon inc div bristol myers squibb
- App pharmaceuticals llc
- Astrazeneca lp
- Baxter healthcare corp anesthesia and critical care
- Hospira inc
- Marsam pharmaceuticals llc
- Teva parenteral medicines inc
- X gen pharmaceuticals inc
- Packagers
- Advanced Pharmaceutical Services Inc.
- Akorn Inc.
- Alcon Laboratories
- Apotex Inc.
- APP Pharmaceuticals
- A-S Medication Solutions LLC
- Bausch & Lomb Inc.
- Bristol-Myers Squibb Co.
- Cardinal Health
- Clipper Distributing Co. LLC
- Darby Dental Supply Co. Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- E.R. Squibb and Sons LLC
- Eye Care and Cure Corp.
- Falcon Pharmaceuticals Ltd.
- H.J. Harkins Co. Inc.
- Hospira Inc.
- Innoviant Pharmacy Inc.
- Keltman Pharmaceuticals Inc.
- Lake Erie Medical and Surgical Supply
- Major Pharmaceuticals
- Medical Ophthalmics
- Medisca Inc.
- MWI Veterinary Supply Co.
- Novartis AG
- Novex Pharma
- Nucare Pharmaceuticals Inc.
- Ocusoft
- Palmetto Pharmaceuticals Inc.
- PD-Rx Pharmaceuticals Inc.
- Pharmedix
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Rebel Distributors Corp.
- Redpharm Drug
- Rx Veterinary Products
- Stat Rx Usa
- Strides Arcolab Limited
- Taylor Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Vedco Inc.
- Wilson Ophthalmic Corp.
- X-Gen Pharmaceuticals
- Dosage Forms
Form Route Strength Powder Respiratory (inhalation) 300 mg Solution Respiratory (inhalation) 300 mg/4mL Solution 100 MG/2ML Solution 150 MG/2ML Spray Respiratory (inhalation) 300 MG/4ML Solution Ophthalmic 300 MG/5ML Solution / drops Auricular (otic) 0.1 % Suspension Ophthalmic 3 mg/ml Solution / drops Intraocular 0.3 % Solution Conjunctival; Ophthalmic 1 mg Solution Conjunctival; Ophthalmic 0.05 mg Ointment Conjunctival; Ophthalmic; Topical 0.3 g Solution / drops Ophthalmic 15 MG/5ML Solution Respiratory (inhalation) 300 mg/5mL Suspension / drops Ophthalmic 0.5 % Suspension Conjunctival; Ophthalmic 5 mg Suspension / drops Ophthalmic 1 MG/ML Liquid Intramuscular; Intravenous Liquid Intravenous Injection, solution Intramuscular; Intravenous 100 MG/2ML Injection, solution Intramuscular; Intravenous 150 MG/2ML Injection, solution Intramuscular; Intravenous 300 mg/4ml Injection, solution Intramuscular; Intravenous 80 MG Injection, solution Parenteral 20 MG/2ML Injection, solution Parenteral 40 MG/ML Solution Conjunctival; Ophthalmic 0.3 g Solution / drops Ophthalmic 0.1 % Ointment Conjunctival; Ophthalmic 0.3 g Solution / drops Ophthalmic 100 mg/100mL Solution / drops Ophthalmic 0.3 % Ointment Ophthalmic 0.3 % Solution Ophthalmic 4.4 mg Ointment Ophthalmic 0.1 g Suspension Auricular (otic) 1 mg Suspension / drops Auricular (otic) 0.1 % Solution / drops Ophthalmic 5 ml Solution Ophthalmic Solution Respiratory (inhalation) Solution / drops Conjunctival 0.3 % Injection Intramuscular; Intravenous 20 mg/2mL Injection Intramuscular; Intravenous 80 mg/2mL Solution Oral 300 mg/5mL Capsule Oral; Respiratory (inhalation) 28 mg/1 Capsule Respiratory (inhalation) 28 mg Powder, metered Respiratory (inhalation) 28 MG Capsule, coated Oral 28 mg Solution Respiratory (inhalation) 300 mg Ointment Ophthalmic Ointment Ophthalmic 0.1 % Suspension Ophthalmic Suspension / drops Ophthalmic 0.1 % Suspension / drops Ophthalmic 100 mg/100mL Ointment Conjunctival; Ophthalmic 0.1 g Ointment Ophthalmic 3 mg Solution / drops Ophthalmic 3 mg Ointment Ophthalmic 1 mg/g Suspension Ophthalmic 1 mg Solution / drops 0.3 % Suspension / drops Ophthalmic 5 mg/mL Solution 300 MG/5ML Injection, solution 1 MG/ML Injection, solution 3 MG/ML Suspension / drops Intraocular 3 MG/ML Injection, solution Parenteral 100 MG/2ML Injection, solution Parenteral 150 MG/2ML Solution Respiratory (inhalation) 60 mg Ointment Ophthalmic; Topical 0.3 g Injection, solution 100 MG/2ML Injection, solution 150 MG/2ML Ointment Conjunctival; Ophthalmic 1 mg Injection Intramuscular; Intravenous 40 mg/1mL Injection Intravenous 1200 mg/30mL Injection, powder, for solution Intravenous 1200 mg/30mL Injection, powder, lyophilized, for solution Intravenous 1.2 g/30mL Injection, solution Intramuscular; Intravenous 10 mg/1mL Injection, solution Intramuscular; Intravenous 40 mg/1mL Injection, solution Intravenous 40 mg/1mL Injection, solution, concentrate Intravenous 10 mg/1mL Solution Ophthalmic 3 mg/1mL Solution Ophthalmic 3.0 mg/1mL Solution Oral 3 mg/1mL Solution Respiratory (inhalation) 60 mg/1mL Solution / drops Ophthalmic 3 mg/1mL Solution / drops Ophthalmic 3.0 mg/1mL Solution / drops Ophthalmic 300 mg/100mL Suspension / drops Ophthalmic Solution Parenteral 1 mg/ml Solution Parenteral 3 mg/ml Powder, for solution Intravenous Injection, solution Intravenous 0.8 mg/1mL Injection, solution Intravenous 1.2 mg/1mL Inhalant Respiratory (inhalation) 300 mg/5mL Solution Intramuscular; Intravenous Liquid Ophthalmic Solution Ophthalmic; Topical 3 mg Injection, solution, concentrate Intravenous 160 mg/2ml Suspension Conjunctival; Ophthalmic 1 mg Suspension / drops Ophthalmic 0.3 % Ointment Ophthalmic 3 mg/1g Ointment Ophthalmic 300 mg/100g Solution Ophthalmic 0.3 % Ointment Ophthalmic 3 mg/g Solution / drops Ophthalmic 3 mg/ml Solution Conjunctival; Ophthalmic 3 mg Ointment Ophthalmic 1 mg Solution 170 MG Suspension / drops Ophthalmic 5 mg/1mL - Prices
Unit description Cost Unit Tobi (1 Box = 56, 5ml Ampules = 280ml Total) 280ml Plastic Container 4461.42USD plastic Tobramycin 1.2 gm vial 338.25USD vial TobraDex 0.3-0.1% Suspension 10ml Bottle 200.43USD bottle TobraDex 0.3-0.1% Ointment 3.5 gm Tube 126.67USD tube TobraDex 0.3-0.1% Suspension 5ml Bottle 98.11USD bottle Tobrex 0.3% Ointment 3.5 gm Tube 80.02USD tube Tobrex 0.3% Solution 5ml Bottle 67.58USD bottle TobraDex 0.3-0.1% Suspension 2.5ml Bottle 54.99USD bottle Tobramycin sulfate powder 53.55USD g Tobradex eye drops 19.27USD ml Tobi 300 mg/5 ml solution 17.58USD ml Tobramycin Sulfate 0.3% Solution 5ml Bottle 15.99USD bottle Tobrex 0.3% eye drops 13.0USD ml Tobi 60 mg/ml Solution 11.4USD ml Tobramycin Sulfate 40 mg/ml Solution 3.6USD ml Tobramycin 40 mg/ml 3.14USD ml Tobramycin 0.3% eye drops 2.99USD ml Aktob 0.3% eye drops 2.85USD ml Tobrex 0.3 % Ointment 2.66USD g Tobramycin 10 mg/ml 2.26USD ml Tobrex 0.3 % Solution 1.88USD ml Pms-Tobramycin 0.3 % Solution 1.05USD ml Sandoz Tobramycin 0.3 % Solution 1.05USD ml Tobramycin 60 mg/50 ml ns 0.19USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region Unlock Additional DataUS5508269 No 1996-04-16 2014-10-19 US US5149694 No 1992-09-22 2009-09-22 US CA2414737 No 2009-01-06 2021-06-26 Canada US7795316 No 2010-09-14 2028-08-03 US US8101582 No 2012-01-24 2027-12-19 US US8450287 No 2013-05-28 2027-12-19 US US7368102 No 2008-05-06 2022-12-19 US US8715623 No 2014-05-06 2022-12-19 US US7559325 No 2009-07-14 2025-10-27 US US7442388 No 2008-10-28 2020-05-10 US US7097827 No 2006-08-29 2016-04-16 US US8349294 No 2013-01-08 2020-05-10 US US8069851 No 2011-12-06 2024-09-24 US US7516741 No 2009-04-14 2024-01-11 US US7939502 No 2011-05-10 2022-06-14 US US6987094 No 2006-01-17 2022-09-22 US US7696178 No 2010-04-13 2023-03-17 US US10207066 No 2019-02-19 2030-11-04 US US8664187 No 2014-03-04 2025-06-20 US US8869794 No 2014-10-28 2028-09-12 US US9421166 No 2016-08-23 2022-12-19 US USRE47526 No 2004-04-09 2024-04-09 US Additional Data Available- Filed OnFiled OnAvailable for Purchase
The date on which a patent was filed with the relevant government.
Learn more
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility 1E+003 mg/ml Not Available logP -5.8 Not Available - Predicted Properties
Property Value Source Water Solubility 53.7 mg/mL ALOGPS logP -3 ALOGPS logP -6.5 ChemAxon logS -0.94 ALOGPS pKa (Strongest Acidic) 12.54 ChemAxon pKa (Strongest Basic) 9.83 ChemAxon Physiological Charge 5 ChemAxon Hydrogen Acceptor Count 14 ChemAxon Hydrogen Donor Count 10 ChemAxon Polar Surface Area 268.17 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 106.69 m3·mol-1 ChemAxon Polarizability 47.18 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.9313 Blood Brain Barrier - 0.9794 Caco-2 permeable - 0.759 P-glycoprotein substrate Substrate 0.5933 P-glycoprotein inhibitor I Non-inhibitor 0.7579 P-glycoprotein inhibitor II Non-inhibitor 0.9086 Renal organic cation transporter Non-inhibitor 0.8412 CYP450 2C9 substrate Non-substrate 0.8361 CYP450 2D6 substrate Non-substrate 0.8333 CYP450 3A4 substrate Non-substrate 0.6662 CYP450 1A2 substrate Non-inhibitor 0.9052 CYP450 2C9 inhibitor Non-inhibitor 0.9359 CYP450 2D6 inhibitor Non-inhibitor 0.923 CYP450 2C19 inhibitor Non-inhibitor 0.9117 CYP450 3A4 inhibitor Non-inhibitor 0.9728 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9398 Ames test Non AMES toxic 0.7537 Carcinogenicity Non-carcinogens 0.9469 Biodegradation Not ready biodegradable 0.9052 Rat acute toxicity 1.7638 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9695 hERG inhibition (predictor II) Non-inhibitor 0.7522
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Trna binding
- Specific Function
- With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Lo...
- Gene Name
- rpsL
- Uniprot ID
- P0A7S3
- Uniprot Name
- 30S ribosomal protein S12
- Molecular Weight
- 13736.995 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Gill AE, Amyes SG: The contribution of a novel ribosomal S12 mutation to aminoglycoside resistance of Escherichia coli mutants. J Chemother. 2004 Aug;16(4):347-9. [PubMed:15332709]
- Yang G, Trylska J, Tor Y, McCammon JA: Binding of aminoglycosidic antibiotics to the oligonucleotide A-site model and 30S ribosomal subunit: Poisson-Boltzmann model, thermal denaturation, and fluorescence studies. J Med Chem. 2006 Sep 7;49(18):5478-90. [PubMed:16942021]
Unknown
Inhibitor
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Doi Y, de Oliveira Garcia D, Adams J, Paterson DL: Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. Antimicrob Agents Chemother. 2007 Mar;51(3):852-6. Epub 2006 Dec 11. [PubMed:17158944]
- Bogaerts P, Galimand M, Bauraing C, Deplano A, Vanhoof R, De Mendonca R, Rodriguez-Villalobos H, Struelens M, Glupczynski Y: Emergence of ArmA and RmtB aminoglycoside resistance 16S rRNA methylases in Belgium. J Antimicrob Chemother. 2007 Mar;59(3):459-64. Epub 2007 Jan 15. [PubMed:17224412]
- Chen SY, Lin TH: A molecular dynamics study on binding recognition between several 4,5 and 4,6-linked aminoglycosides with A-site RNA. J Mol Recognit. 2010 Sep-Oct;23(5):423-34. doi: 10.1002/jmr.1008. [PubMed:20029836]
Enzymes
- Kind
- Protein
- Organism
- Mycobacterium tuberculosis
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- May catalyze the coenzyme A-dependent acetylation of the 2' hydroxyl or amino group of a broad spectrum of aminoglycosides and confer resistance to aminoglycosides (By similarity). In vitro assays show no significant increase of resistance to aminoglycosides, possibly due to low expression in a heterologous system (PubMed:9159528).
- Specific Function
- Aminoglycoside 2'-n-acetyltransferase activity
- Gene Name
- aac
- Uniprot ID
- P9WQG9
- Uniprot Name
- Aminoglycoside 2'-N-acetyltransferase
- Molecular Weight
- 20037.53 Da
References
- Vetting MW, Hegde SS, Javid-Majd F, Blanchard JS, Roderick SL: Aminoglycoside 2'-N-acetyltransferase from Mycobacterium tuberculosis in complex with coenzyme A and aminoglycoside substrates. Nat Struct Biol. 2002 Sep;9(9):653-8. [PubMed:12161746]
Drug created on June 13, 2005 07:24 / Updated on January 16, 2021 12:52
